Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 3Recruiting 2Not yet recruiting 2Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Colorectal Neoplasms 17Breast Neoplasms 14Rectal Neoplasms 12Nasopharyngeal Carcinoma 8Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Biliary Tract Neoplasms 3Adenocarcinoma 3Recurrence 2Pancreatic Neoplasms 2HER2-positive Gastric Cancer 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Spinocerebellar Degenerations 1Rectal Neoplasms Malignant 1Rectal Cancer Patients 1Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Pancreatic Cancer Non-resectable 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Cancinoma (NPC) 1Mouth Neoplasms 1Metastatic Breast Cancer in the Brain 1MSI-H Colorectal Cancer 1Locally Advanced Rectal Cancer (LARC) 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × Capecitabine × Clear all
NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Recurrence

NCT06892431 2025-03-25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
150 enrolled
Head & Neck

Nasopharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡